Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial.,JAMA Neurology

当前位置： X-MOL 学术 › JAMA Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Neurology ( IF 29.0 ) Pub Date : 2023-12-18 , DOI: 10.1001/jamaneurol.2023.4719
Wagner S. Brum _{1,

2} , Kieran F. Docherty ₃ , Nicholas J. Ashton _{1,

4,

5,

6} , Henrik Zetterberg _{1,

7,

8,

9,

10} , Oskar Hansson _{10,

11} , John J. V. McMurray ₃ , Kaj Blennow _{1,

7}

Affiliation

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, United Kingdom
National Institute for Health and Care Research Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, United Kingdom
Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, United Kingdom
UK Dementia Research Institute, University College London, London, United Kingdom
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden

This exploratory analysis of a randomized clinical trial evaluates the effect of neprilysin inhibition on Alzheimer disease blood biomarkers in patients with heart disease.

中文翻译：